<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873468</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0115</org_study_id>
    <nct_id>NCT02873468</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis</brief_title>
  <official_title>Clinical Study, Multicentre, Parallel, Double-blind, Randomized for the Dose to Evaluate the Safety and Efficacy of Three Doses of Oral Fluticasone Propionate Compared to Placebo in Adults With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of three doses of fluticasone
      propionate oral (viscous suspension) on changes of eosinophilic infiltration in esophageal
      biopsies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of three doses of fluticasone propionate oral by evaluating changes of eosinophilic infiltration in esophageal biopsies</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>EMS Fluticasone 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will take 4,5mL, oral, BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMS Fluticasone 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will take 7mL, oral, BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMS Fluticasone 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will take 9mL, oral, BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMS Placebo Fluticasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will take 5mL, oral, BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMS Fluticasone 1</intervention_name>
    <description>The patient will take 4,5mL, oral, BID.</description>
    <arm_group_label>EMS Fluticasone 1</arm_group_label>
    <other_name>Fluticasone Propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMS Fluticasone 2</intervention_name>
    <description>The patient will take 7mL, oral, BID.</description>
    <arm_group_label>EMS Fluticasone 2</arm_group_label>
    <other_name>Fluticasone Propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMS Fluticasone 3</intervention_name>
    <description>The patient will take 9mL, oral, BID.</description>
    <arm_group_label>EMS Fluticasone 3</arm_group_label>
    <other_name>Fluticasone Propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EMS Placebo Fluticasone</intervention_name>
    <description>The patient will take 5mL, oral, BID.</description>
    <arm_group_label>EMS Placebo Fluticasone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Consent of the patient;

          -  Participants presenting eosinophilic esophagitis confirmed by endoscopy with 15
             eosinophils/hpf and clinical symptoms;

        Exclusion Criteria:

          -  Patients with any clinically significant disease that in the investigator opinion
             they can´t participate in the study;

          -  Patients with any laboratory finding or image finding that in the investigator
             opinion they can´t participate in the clinical trial;

          -  Patients with history of hypersensitivity to any of the formula compounds;

          -  Participation in clinical trial in the year prior to this study;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Patients with diseases of the esophagus / erosive esophagitis;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce M. Silva, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
